Inhibitor Therapeutics, Inc.
INTI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.86M
Close$
$0.01
78.1% downside
Current Fair Value
78.1% downsideOvervalued by 78.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.86 Million |
|---|---|
| Enterprise Value | $19.39 Million |
| Earnings per Share | $-0.02 |
| Beta | -0.68 |
| Outstanding Shares | 173,307,525 |
Return
| Return on Equity | 129.25% |
|---|---|
| Return on Assets | -519.14% |
| Return on Invested Capital | -722.81% |
Valuation & Multiples
| P/E Ratio | -5.08 |
|---|---|
| PEG | 72.85 |
| Price to Sales | - |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.8 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -1.19 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Inhibitor Therapeutics, Inc.
8 employees
CEO: Francis E. O'Donnell Jr.
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who...